Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2013-09-11 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by the company's board regarding stock pledge guarantees and a commitment letter from the actual controller of the company. It discusses stock pledges, risk mitigation related to control of the company, and a commitment to maintain control. There is no financial report, no meeting materials, no voting results, no legal proceedings, no earnings data, and no mention of a report being attached or published. The document is a regulatory announcement about share pledges and control assurances, which fits best under Regulatory Filings (RNS) as it does not fit any other specific category.
2013-09-11 Chinese
关于非公开发行股票相关事项的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a non-public issuance of shares by the company 中源协和干细胞生物工程股份公司. It details the source of funds for a controlling shareholder's subscription to the shares and mentions approval by the China Securities Regulatory Commission. The content focuses on financing activities related to share issuance, specifically a non-public offering and related funding arrangements. The document length is short (553 characters), and it is not a report or financial statement but an announcement about capital raising activities. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2013-09-11 Chinese
关于下属企业收到政府补助资金的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (527 characters) regarding a government subsidy received by a subsidiary of the company. It includes details about the subsidy amount, accounting treatment, and the date of receipt. There is no detailed financial report or comprehensive analysis, only a disclosure of a specific event affecting the company. The document is not a full financial report, audit, or earnings release. It is an official announcement related to a regulatory or compliance matter. Given the short length and nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2013-09-04 Chinese
关于独立董事辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of an independent director from the company's board. It details the resignation date, reasons, and confirms compliance with legal requirements for board composition. There is no financial data, no report attached or referenced, and no mention of voting results or other categories. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2013-08-19 Chinese
第七届董事会第二十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from the company 中源协和干细胞生物工程股份公司. It details the approval of the company's 2013 semi-annual report and a supplementary explanation regarding a non-public stock issuance profit distribution policy. The document is short (607 characters) and primarily announces the board's decisions rather than containing the full semi-annual report or detailed financial data. Therefore, it is not the interim/quarterly report itself but an announcement of board resolutions related to such reports and policies. This fits best under Board/Management Information (MANG) as it concerns board meeting resolutions and decisions.
2013-08-16 Chinese
关于近五年被证券监管部门和上海证券交易所采取监管措施或处罚及整改情况的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding regulatory measures, penalties, and rectification actions taken by securities regulatory authorities and the Shanghai Stock Exchange over the past five years. It details specific regulatory notices, criticisms, and corrective measures related to compliance, governance, and financial reporting issues. The document does not contain financial statements or detailed financial performance data, nor is it a transcript, presentation, or voting result. It is a regulatory compliance and disclosure announcement about past regulatory actions and company responses. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2013-08-16 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.